A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease

BACKGROUND: Overall survival of HER2 positive metastatic breast cancer patients has been significantly improved with inclusion of trastuzumab to chemotherapy. Several studies have demonstrated discordant HER2 status in the primary and metastatic tumour. However, rates of discordance vary considerabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Arlene, Morey, Adrienne, Brown, Belinda, Hastrich, Diana, Willsher, Peter, Ingram, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517741/
https://www.ncbi.nlm.nih.gov/pubmed/23176370
http://dx.doi.org/10.1186/1471-2407-12-555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517741/
https://www.ncbi.nlm.nih.gov/pubmed/23176370
http://dx.doi.org/10.1186/1471-2407-12-555

Ejemplares similares